Ascites and Spontaneous Bacterial Peritonitis

1. Clinical Overview

Summary

Ascites is the pathological accumulation of fluid in the peritoneal cavity, occurring in 50% of patients with compensated cirrhosis within 10 years of diagnosis. It represents a critical transition from compensated to decompensated cirrhosis, with median survival dropping from 12 years to 2-4 years upon development. The most common cause is portal hypertension secondary to cirrhosis (85%), with cardiac and malignant causes comprising the remainder.

Spontaneous bacterial peritonitis (SBP) is an acute infection of ascitic fluid in the absence of an intra-abdominal surgically treatable source. It occurs almost exclusively in patients with cirrhosis and ascites, affecting 10-30% of hospitalized cirrhotic patients. SBP arises through bacterial translocation from the gut, typically with Gram-negative enteric organisms. In-hospital mortality remains 20-40%, and SBP triggers hepatorenal syndrome in approximately 30% of cases. Without secondary prophylaxis, recurrence rate approaches 70% within one year.

The serum-ascites albumin gradient (SAAG) is the gold standard for classification: SAAG ≥11 g/L (≥1.1 g/dL) indicates portal hypertension-related ascites with 97% accuracy. Management depends on severity: first-line is dietary sodium restriction and diuretics (spironolactone with or without furosemide), escalating to large-volume paracentesis with albumin replacement for tense ascites, and transjugular intrahepatic portosystemic shunt (TIPS) for refractory ascites.

Early diagnosis of SBP through diagnostic paracentesis is critical. Treatment with third-generation cephalosporins combined with intravenous albumin (Day 1 and Day 3) reduces hepatorenal syndrome and mortality by approximately 50%. Lifelong secondary prophylaxis with norfloxacin or ciprofloxacin prevents recurrence and should be initiated after the first SBP episode.

Key Facts

Ascites:

• Incidence: 50% of compensated cirrhotic patients develop ascites within 10 years
• Survival impact: Median survival drops from 12 years (compensated) to 2-4 years (with ascites)
• SAAG diagnostic accuracy: ≥11 g/L indicates portal hypertension with 97% sensitivity
• Refractory ascites: Occurs in 5-10% of patients with cirrhotic ascites
• 1-year mortality with refractory ascites: 50%

Spontaneous Bacterial Peritonitis:

• Prevalence: 10-30% of hospitalized cirrhotic patients with ascites
• Causative organisms: E. coli (40%), Klebsiella (15%), Streptococcus pneumoniae (10%)
• Diagnostic threshold: Ascitic fluid neutrophil count ≥250 cells/mm³
• In-hospital mortality: 20-40%
• Hepatorenal syndrome risk: Develops in 30% of SBP cases
• 1-year mortality post-SBP: 50-70%
• Recurrence without prophylaxis: 70% at 1 year
• Key treatment: IV cefotaxime 2g TDS + IV albumin (1.5 g/kg Day 1, 1 g/kg Day 3)

Clinical Pearls

Tap First, Ask Questions Later: Any cirrhotic patient presenting unwell should have a diagnostic paracentesis performed urgently. SBP can present with fever, abdominal pain, encephalopathy, renal deterioration — or with no symptoms at all in up to 30% of cases. Empirical antibiotics should not be delayed while awaiting culture results.

SAAG Not Protein: The traditional "exudate-transudate" classification based on ascitic fluid protein is obsolete. SAAG ≥11 g/L accurately identifies portal hypertension-related ascites irrespective of protein content. Low ascitic protein (less than 15 g/L) identifies patients at high risk for SBP, not the etiology of ascites.

The Albumin Protocol Saves Lives: IV albumin (1.5 g/kg on Day 1 up to maximum 100g, and 1 g/kg on Day 3 up to maximum 100g) administered with antibiotics reduces hepatorenal syndrome from 33% to 10% and mortality from 29% to 10%. This is now standard of care for all SBP patients, particularly those with creatinine > 88 μmol/L (> 1 mg/dL) or bilirubin > 68 μmol/L (> 4 mg/dL).

Diuretic Ratio Matters: Spironolactone and furosemide should be initiated or increased in a 100:40 ratio (e.g., spironolactone 100 mg with furosemide 40 mg) to maintain normokalemia while achieving diuresis. Single-agent spironolactone is acceptable initially to avoid electrolyte disturbances.

One Episode = Prophylaxis for Life: After one episode of SBP, lifelong secondary prophylaxis with norfloxacin 400mg OD or ciprofloxacin 500mg OD is mandatory due to 70% recurrence rate. Discontinue only if ascites resolves completely or patient undergoes liver transplantation.

Paracentesis is Safe: Large-volume paracentesis (> 5L) is safe even in the presence of coagulopathy. Prophylactic blood products are not required even with INR > 1.5 or platelets > 50×10⁹/L. Bleeding risk is less than 1% and related to technique, not laboratory parameters.

Culture Bottle Inoculation: Ascitic fluid should be inoculated into blood culture bottles at the bedside (10mL per aerobic and anaerobic bottle) to maximize culture yield, which increases from 40% with conventional methods to 80% with this technique.

Why This Matters Clinically

Ascites marks a critical prognostic transition in chronic liver disease. Its development mandates liver transplant evaluation and aggressive management to prevent life-threatening complications including SBP, hepatorenal syndrome, and respiratory compromise from tense ascites.

SBP is frequently under-recognized because symptoms can be subtle or absent. Delayed diagnosis and treatment lead to sepsis, multi-organ failure, hepatorenal syndrome, and death. A low threshold for diagnostic paracentesis in any unwell cirrhotic patient is essential for early diagnosis. The combination of antibiotics with albumin represents one of the most evidence-based interventions in hepatology, with robust RCT data demonstrating dramatic reduction in mortality and renal complications.

---

2. Epidemiology

Incidence & Prevalence

Ascites:

• Prevalence in cirrhosis: 50% develop ascites within 10 years of diagnosis
• Annual incidence in compensated cirrhosis: Approximately 7-10%
• Refractory ascites: 5-10% of patients with cirrhotic ascites
• Etiological distribution:
  • "Portal hypertension (cirrhosis): 85%"
  • "Malignancy (peritoneal carcinomatosis): 10%"
  • "Cardiac failure: 3%"
  • "Other (pancreatitis, tuberculosis, nephrotic syndrome): 2%"

Spontaneous Bacterial Peritonitis:

• Hospital prevalence: 10-30% of cirrhotic patients admitted with ascites
• Community prevalence: 1.5-3.5% of outpatients with cirrhotic ascites
• Incidence in ascites: Approximately 8-15 episodes per 100 patient-years
• Culture-negative neutrocytic ascites (CNNA): Comprises 40-50% of SBP cases
• Nosocomial SBP: 30-40% of all SBP cases, associated with higher mortality and multidrug-resistant organisms
• Recurrence without prophylaxis: 70% at 1 year, 50% by 6 months

Demographics

Risk Factors

Risk Factors for Developing Ascites in Cirrhosis:

Risk Factors for Spontaneous Bacterial Peritonitis:

Natural History & Prognosis

Ascites Development and Survival:

• Compensated cirrhosis → Development of ascites marks transition to decompensation
• Median survival before ascites: 12 years
• Median survival after ascites develops: 2-4 years
• 1-year survival with first ascites: 80-85%
• 5-year survival with ascites: 30-40%
• Median survival with refractory ascites: 6 months (without TIPS or transplant)

SBP Outcomes:

• In-hospital mortality: 20-40%
• 30-day mortality: 25-30%
• 1-year mortality: 50-70%
• Recurrence without secondary prophylaxis: 70% at 1 year
• Recurrence with secondary prophylaxis: less than 20% at 1 year
• Hepatorenal syndrome develops in 30% of SBP episodes

---

3. Pathophysiology

Ascites Formation: Pathophysiological Mechanisms

Ascites in cirrhosis results from a complex interplay of portal hypertension, splanchnic vasodilation, renal sodium retention, and hypoalbuminemia. The classical "underfill" and "overflow" hypotheses have been replaced by the peripheral arterial vasodilation hypothesis, which integrates hemodynamic and renal mechanisms.

Step 1: Portal Hypertension

Portal hypertension (portal pressure > 5 mmHg above IVC pressure) is the initiating event. Clinically significant portal hypertension (≥10 mmHg, or hepatic venous pressure gradient HVPG ≥10 mmHg) is required for ascites formation.

Mechanisms:

• Increased intrahepatic resistance: Architectural distortion from fibrosis, sinusoidal remodeling, endothelial dysfunction, and hepatic stellate cell contraction
• Increased portal venous inflow: Splanchnic vasodilation mediated by nitric oxide (NO), carbon monoxide, and other vasodilators leads to increased blood flow into the portal system despite elevated pressure
• Sinusoidal pressure transmission: Elevated sinusoidal pressure drives fluid transudation across hepatic capsule into peritoneal cavity

Step 2: Splanchnic and Systemic Vasodilation

Peripheral arterial vasodilation hypothesis:

• Portal hypertension triggers splanchnic vasodilation via increased NO production by gut endothelium
• Systemic arterial vasodilation follows, causing "effective" arterial hypovolemia despite total body fluid overload
• Vasodilation is sensed by arterial baroreceptors as reduced effective circulating volume

Vasodilatory mediators:

• Nitric oxide (NO) – primary mediator
• Carbon monoxide
• Endocannabinoids
• Glucagon
• Prostacyclin

Step 3: Renal Sodium and Water Retention

Perceived hypovolemia activates compensatory neurohormonal systems:

Renin-Angiotensin-Aldosterone System (RAAS):

• Increased renin secretion → angiotensin II → aldosterone
• Aldosterone promotes distal tubular sodium reabsorption
• Primary target of spironolactone (aldosterone antagonist)

Sympathetic Nervous System (SNS):

• Increased renal sympathetic tone → afferent arteriolar vasoconstriction → reduced glomerular filtration
• Promotes proximal tubular sodium reabsorption

Antidiuretic Hormone (ADH/Vasopressin):

• Non-osmotic release due to perceived hypovolemia
• Water retention → dilutional hyponatremia (common in advanced cirrhosis)

Result: Progressive sodium and water retention despite total body volume expansion, perpetuating ascites accumulation.

Step 4: Hypoalbuminemia and Reduced Oncotic Pressure

• Hepatic synthetic dysfunction → reduced albumin production
• Serum albumin less than 30 g/L impairs intravascular oncotic pressure
• Oncotic-hydrostatic imbalance favors fluid extravasation into peritoneal cavity
• Note: Hypoalbuminemia alone does not cause ascites without portal hypertension

Step 5: Lymphatic Insufficiency

• Hepatic and intestinal lymph production increases 20-fold in cirrhosis
• Lymphatic drainage capacity is overwhelmed
• Excess lymph "weeps" from hepatic capsule and mesenteric surfaces into peritoneal cavity

Spontaneous Bacterial Peritonitis: Pathophysiological Mechanisms

SBP results from bacterial translocation from the gut into ascitic fluid, combined with impaired host immune defenses.

Step 1: Bacterial Overgrowth and Altered Gut Microbiome

Cirrhosis-related gut changes:

• Reduced gut motility: Decreased intestinal transit time promotes bacterial overgrowth
• Altered bile acid metabolism: Reduced bactericidal bile acids in gut lumen
• Proton pump inhibitors: Alter gastric pH and gut microbiome (controversial association)
• Small intestinal bacterial overgrowth (SIBO): Present in 30-50% of cirrhotic patients

Result: Increased intestinal bacterial load and shift toward pathogenic Gram-negative organisms (E. coli, Klebsiella).

Step 2: Increased Intestinal Permeability and Bacterial Translocation

Intestinal barrier dysfunction in cirrhosis:

• Portal hypertension: Causes intestinal edema, mucosal congestion, and increased permeability
• Splanchnic vasodilation: Impairs mucosal perfusion
• Disrupted tight junctions: Inflammatory cytokines (TNF-α, IL-6) weaken epithelial barrier
• Reduced secretory IgA: Impaired mucosal immunity

Bacterial translocation pathway:

• Bacteria cross compromised intestinal epithelium
• Enter mesenteric lymph nodes
• Access bloodstream via portal and lymphatic routes
• Reach ascitic fluid through peritoneal capillaries or direct bacterial translocation across gut wall

GI bleeding amplifies risk: Mucosal injury and blood in gut lumen dramatically increase bacterial translocation, explaining 20-40% SBP risk with variceal hemorrhage.

Step 3: Impaired Ascitic Fluid Host Defenses

Low opsonic activity:

• Ascitic fluid with protein less than 15 g/L has markedly reduced complement (C3) and IgG
• Impaired opsonization → inadequate bacterial phagocytosis
• Explains why low ascitic protein is the strongest predictor of SBP risk

Impaired neutrophil function:

• Cirrhotic patients have neutrophil dysfunction with reduced chemotaxis, phagocytosis, and oxidative burst
• Despite elevated neutrophil count, functional capacity is impaired

Reduced reticuloendothelial clearance:

• Hepatic and splenic macrophage dysfunction
• Impaired clearance of bacteria from portal blood

Step 4: Peritoneal Infection and Systemic Inflammation

• Bacterial multiplication in ascitic fluid
• Neutrophil recruitment (PMN ≥250/mm³ defines SBP)
• Inflammatory cytokine release (TNF-α, IL-6, IL-1β)
• Systemic inflammatory response syndrome (SIRS) in severe cases
• Hepatorenal syndrome risk: Inflammatory cytokines cause renal vasoconstriction and acute kidney injury in 30% of SBP

Classification of Ascitic Fluid Infections

Distinguishing Secondary from Spontaneous Peritonitis (Runyon's Criteria): Two or more of the following suggest secondary peritonitis:

• Total protein > 10 g/L
• Glucose less than 50 mg/dL (2.8 mmol/L)
• LDH greater than upper limit of normal for serum
• Polymicrobial culture

Common Causative Organisms in SBP

Monomicrobial Gram-negative (70%):

• Escherichia coli (40%)
• Klebsiella pneumoniae (15%)
• Other Enterobacteriaceae (10-15%)

Gram-positive (20-30%):

• Streptococcus pneumoniae (10%)
• Enterococcus species (5-10%)
• Streptococcus viridans (5%)
• Staphylococci (rare, consider secondary peritonitis or catheter-related)

Anaerobes (less than 5%):

• Rare in spontaneous peritonitis; presence suggests secondary peritonitis

Nosocomial SBP organisms:

• Increased multidrug-resistant (MDR) organisms
• ESBL-producing Enterobacteriaceae
• Methicillin-resistant Staphylococcus aureus (MRSA)
• Pseudomonas aeruginosa
• Enterococcus (including VRE)

Molecular and Cellular Mechanisms

Pattern Recognition and Innate Immunity:

• Bacterial pathogen-associated molecular patterns (PAMPs) recognized by Toll-like receptors (TLRs) on peritoneal macrophages and mesothelial cells
• TLR4 (LPS receptor) and TLR2 activation trigger NF-κB signaling
• Cytokine production: TNF-α, IL-1β, IL-6, IL-8
• Neutrophil chemotaxis via IL-8 and complement fragments (C5a)

Complement System Dysfunction:

• Low C3 in ascitic fluid (less than 15 mg/dL) predicts SBP
• Impaired opsonization and reduced membrane attack complex formation
• Alternative pathway activation is impaired in low-protein ascites

Endotoxemia and Systemic Effects:

• Bacterial endotoxin (LPS) enters systemic circulation
• Triggers systemic inflammation, hypotension, and renal vasoconstriction
• Contributes to hepatorenal syndrome pathogenesis
• Albumin infusion may bind endotoxin and reduce inflammatory response (theoretical mechanism)

---

4. Clinical Presentation

Ascites: Symptoms

Early/Uncomplicated Ascites:

• Abdominal distension (progressive, often insidious)
• Weight gain
• Increased abdominal girth (patients may notice tight clothing or belt loosening)
• Early satiety (gastric compression)
• Dyspepsia, nausea

Moderate to Tense Ascites:

• Marked abdominal distension and discomfort
• Dyspnea (diaphragmatic splinting, pleural effusion)
• Orthopnea
• Lower limb edema (venous and lymphatic compression)
• Reduced mobility
• Umbilical or inguinal hernia (increased intra-abdominal pressure)

Complications:

• Spontaneous bacterial peritonitis: Fever, abdominal pain, altered mental status
• Hepatic hydrothorax: Right-sided pleural effusion (85%), dyspnea, hypoxia
• Tense ascites: Respiratory compromise, umbilical hernia rupture (rare but life-threatening)
• Hepatorenal syndrome: Oliguria, rising creatinine

Ascites: Signs

Inspection:

• Abdominal distension with flank bulging
• Everted umbilicus
• Dilated superficial abdominal veins (caput medusae if portal hypertension)
• Umbilical or inguinal hernias
• Striae distensae
• Peripheral stigmata of chronic liver disease: jaundice, spider naevi, palmar erythema, leukonychia, clubbing, gynecomastia, testicular atrophy, muscle wasting

Percussion:

• Shifting dullness: Detects ≥1500 mL of ascites (sensitivity 83%, specificity 56%)
• Fluid wave/thrill: Requires larger volume (> 3000 mL); less sensitive but more specific
• Resonance in umbilical region with flanks dull (fluid gravitates to dependent areas in supine position)

Palpation:

• Tense, non-tender abdomen (unless SBP or other complication)
• Hepatomegaly may be difficult to assess due to fluid
• Splenomegaly (portal hypertension)

Other Signs:

• Reduced breath sounds at lung bases (hepatic hydrothorax, especially right-sided)
• Asterixis (hepatic encephalopathy)
• Fetor hepaticus

Spontaneous Bacterial Peritonitis: Symptoms

Classic Presentation (50-70%):

• Fever (50-80%) – may be low-grade or absent in advanced cirrhosis
• Abdominal pain or discomfort (50%) – typically diffuse, mild-moderate
• Altered mental status or new/worsening hepatic encephalopathy (30%)
• Nausea, vomiting, diarrhea
• General malaise

Subtle or Asymptomatic Presentation (10-30%):

• No fever or abdominal pain
• Unexplained clinical deterioration
• Worsening renal function or encephalopathy alone
• Incidental finding on routine diagnostic paracentesis

Severe/Septic Presentation:

• Severe sepsis or septic shock (10-20%)
• Hypotension, tachycardia
• Acute kidney injury (hepatorenal syndrome)
• Multi-organ dysfunction

Associated Features:

• Gastrointestinal bleeding (preceding or concurrent in 20-40%)
• Acute-on-chronic liver failure
• Precipitant events: recent procedures, hospitalization (nosocomial SBP)

Spontaneous Bacterial Peritonitis: Signs

Abdominal Examination:

• Diffuse, mild-to-moderate abdominal tenderness (common)
• Rebound tenderness or peritonism (less frequent than in surgical peritonitis)
• Tense ascites (if large volume)
• Absent or reduced bowel sounds (ileus in severe cases)

Systemic Signs:

• Fever (may be absent in 20-50%, especially if advanced cirrhosis)
• Tachycardia
• Hypotension (septic shock in severe cases)
• Tachypnea
• Hypothermia (poor prognostic sign)

Encephalopathy:

• Confusion, disorientation
• Asterixis (hepatic flap)
• Drowsiness to coma (West Haven Grade I-IV)

Signs of Decompensated Cirrhosis:

• Jaundice (often worsens with SBP)
• Ascites
• Peripheral edema
• Muscle wasting

Red Flags – Immediate Diagnostic Paracentesis Required

[!CAUTION] Immediate Paracentesis and Empirical Antibiotics Indicated if ANY of the Following:

• Any fever (even low-grade) in cirrhotic patient with ascites
• New or worsening hepatic encephalopathy (altered mental status, confusion, asterixis)
• Worsening renal function (rising creatinine, oliguria)
• Abdominal pain or tenderness in patient with ascites
• Hypotension or signs of sepsis (tachycardia, hypotension, shock)
• Gastrointestinal bleeding (20-40% develop SBP)
• Unexplained clinical deterioration in cirrhotic patient
• Routine screening: All patients hospitalized with ascites should undergo diagnostic paracentesis on admission

Do not delay paracentesis for coagulopathy correction: INR and platelet count do not predict bleeding risk. Paracentesis is safe with INR > 2.0 and platelets > 50×10⁹/L without prophylactic transfusion.

---

5. Clinical Examination

Structured Examination for Ascites

General Inspection:

• Vital signs: Blood pressure, heart rate, temperature, respiratory rate, oxygen saturation
• Nutritional status and muscle wasting (sarcopenia common in cirrhosis)
• Jaundice, pallor
• Asterixis (extend wrists for 30 seconds)
• Peripheral stigmata of chronic liver disease

Abdominal Examination:

1. Inspection:

   • Distension with bulging flanks
   • Umbilical eversion or hernias
   • Dilated superficial veins (caput medusae)
   • Scars (previous paracentesis, surgery)

2. Palpation:

   • Start away from areas of tenderness
   • Assess for hepatomegaly (liver may be impalpable if cirrhotic and surrounded by ascites)
   • Splenomegaly (suggests portal hypertension)
   • Tenderness (localized vs. diffuse)
   • Hernias (umbilical, inguinal)

3. Percussion:

   • Shifting dullness technique (detects ≥1500 mL):
     • Percuss from umbilicus toward flank until dullness
     • Mark transition point
     • Roll patient to opposite side, wait 30 seconds
     • Re-percuss at same point; dullness shifts to new dependent flank = positive test
   • Fluid wave/thrill (detects ≥3000 mL):
     • Assistant places edge of hand vertically on midline abdomen
     • Tap one flank; feel for transmitted wave on opposite flank
     • Less sensitive but more specific than shifting dullness

4. Auscultation:

   • Bowel sounds (ileus may occur in SBP)

Respiratory Examination:

• Reduced breath sounds at lung bases (hepatic hydrothorax, usually right-sided)
• Dullness to percussion at bases
• Tachypnea if tense ascites or hydrothorax

Cardiovascular Examination:

• Jugular venous pressure (assess for cardiac ascites)
• Heart sounds (murmurs, rubs, gallops suggest cardiac cause)
• Peripheral edema

Neurological Examination:

• Mental status (encephalopathy grading: West Haven Criteria Grade 0-IV)
• Asterixis (best elicited with wrists extended, fingers spread; observe for flapping tremor)

Special Tests

---

6. Investigations

First-Line Investigations for Ascites

Diagnostic Paracentesis (MANDATORY for all new-onset ascites and admitted patients):

• Perform on all patients with new-onset ascites
• Perform on all hospitalized patients with ascites (regardless of symptoms)
• Send 30-50 mL of ascitic fluid for analysis

Ascitic Fluid Analysis (send to lab immediately):

Simultaneous Serum Tests:

• Serum albumin (essential for SAAG calculation)
• Full blood count (FBC)
• Urea, creatinine, electrolytes (renal function)
• Liver function tests (bilirubin, ALT, AST, ALP, albumin, INR)
• C-reactive protein (CRP) or procalcitonin (if SBP suspected)

SAAG Calculation and Interpretation

Serum-Ascites Albumin Gradient (SAAG) = Serum Albumin − Ascitic Fluid Albumin

Interpretation:

Note: SAAG remains accurate even in patients with infection, hemorrhage, or multiple causes of ascites.

Ascitic Fluid Protein and SBP Risk

Diagnostic Criteria for Spontaneous Bacterial Peritonitis

SBP Diagnosis:

• Ascitic fluid PMN count ≥250 cells/mm³ (0.25 × 10⁹/L)
• Monomicrobial culture (or culture-negative)
• No surgical source of infection

Start empirical antibiotics immediately when PMN ≥250/mm³; do not wait for culture results.

Paracentesis Technique

Indications:

• All new-onset ascites
• All hospitalized patients with ascites (routine)
• Suspected SBP (any fever, abdominal pain, encephalopathy, or clinical deterioration)
• Therapeutic drainage (tense ascites)

Site Selection:

• Preferred site: Left lower quadrant (LLQ), midway between umbilicus and anterior superior iliac spine, approximately 2-3 cm medial and 2-3 cm superior to ASIS
• Alternative: Right lower quadrant (RLQ) at equivalent position
• Avoid: Midline (risk of inferior epigastric vessels), previous surgical scars, organomegaly, visible collaterals

Technique:

1. Position: Supine with slight lateral tilt (fluid gravitates to dependent side)
2. Ultrasound guidance: Recommended (especially if small ascites, obesity, previous surgery); mark pocket if real-time guidance unavailable
3. Sterile technique: Skin prep with chlorhexidine; sterile gloves and drape
4. Local anesthesia: 1% lidocaine to skin, subcutaneous tissue, and peritoneum
5. Needle insertion: Use 20-22G needle (diagnostic) or larger catheter (therapeutic)
   • Insert perpendicular to skin or at slight angle
   • "Z-track" technique (displace skin laterally before insertion) reduces leak
   • Aspirate as advancing until fluid returns
6. Fluid collection:
   • Diagnostic: 30-50 mL into appropriate tubes
   • Therapeutic: Attach catheter to drainage bag; remove up to 10L (no restriction on volume if albumin administered)
7. Post-procedure: Apply pressure; small dressing

Coagulopathy and Paracentesis:

• Paracentesis is safe with INR > 2.0 and platelets > 50 × 10⁹/L
• No prophylactic blood products required unless:
  • Platelet count less than 20 × 10⁹/L (consider platelet transfusion)
  • Clinical bleeding or DIC
  • Concurrent procedure (e.g., biopsy)
• Bleeding risk less than 1%; related to technique (avoid vessels), not laboratory parameters

Laboratory Tests (Serum)

Imaging

Ultrasound Abdomen:

• First-line imaging for ascites detection and characterization
• Detects as little as 100 mL (far more sensitive than clinical exam)
• Assess:
  • Presence and volume of ascites
  • Liver size, echogenicity, nodularity (cirrhosis)
  • Splenomegaly (portal hypertension)
  • Portal vein patency and direction of flow (Doppler)
  • Hepatocellular carcinoma screening (if cirrhotic)
  • Guide paracentesis (mark pocket or real-time guidance)

CT Abdomen/Pelvis with Contrast:

• If secondary peritonitis suspected (free air, bowel perforation, abscess)
• If malignancy suspected (peritoneal/omental nodules, masses)
• Evaluation for hepatocellular carcinoma
• TIPS planning

Chest X-ray:

• Assess for hepatic hydrothorax (right-sided pleural effusion in 85%)
• Exclude pulmonary infection

Echocardiography:

• If cardiac ascites suspected (raised JVP, peripheral edema, clinical heart failure)
• Assess left and right ventricular function, valvular disease, pericardial effusion/constriction

Additional Investigations for Refractory or Unclear Ascites

Hepatic Venous Pressure Gradient (HVPG):

• Gold standard for assessing portal hypertension
• HVPG ≥10 mmHg indicates clinically significant portal hypertension
• HVPG ≥12 mmHg associated with variceal bleeding and ascites

Diagnostic Laparoscopy with Peritoneal Biopsy:

• If tuberculous peritonitis or peritoneal carcinomatosis suspected and ascitic cytology/imaging inconclusive
• Directly visualize peritoneum; biopsy for histology and culture

Serum CA-125:

• Elevated in peritoneal carcinomatosis
• Also elevated in cirrhotic ascites (false positive); limited specificity

---

7. Management

Management Algorithm for Ascites

                  NEW-ONSET ASCITES
                         ↓
        ┌────────────────────────────────────┐
        │   DIAGNOSTIC PARACENTESIS          │
        │   + Serum Albumin (calculate SAAG) │
        │   + Liver function, renal function  │
        │   + Ultrasound abdomen              │
        └────────────────────────────────────┘
                         ↓
        ┌────────────────────────────────────┐
        │ SAAG ≥11 g/L → Portal Hypertension │
        │ (Treat underlying liver disease)    │
        │                                     │
        │ SAAG less than 11 g/L → Non-portal causes   │
        │ (Malignancy, TB, pancreas, etc.)   │
        └────────────────────────────────────┘
                         ↓
            ┌────────────────────────┐
            │  GRADE ASCITES         │
            ├────────────────────────┤
            │ Grade 1 (mild)         │
            │ Grade 2 (moderate)     │
            │ Grade 3 (tense/severe) │
            └────────────────────────┘
                         ↓
┌────────────────────────────────────────────────────┐
│              ASCITES MANAGEMENT                    │
├────────────────────────────────────────────────────┤
│ Grade 1 (Mild):                                    │
│  - Sodium restriction (less than 2 g/day = 90 mmol/day)     │
│  - Monitor; diuretics if progression               │
│                                                    │
│ Grade 2 (Moderate):                                │
│  - Sodium restriction (less than 2 g/day)                   │
│  - Spironolactone 100 mg OD (± furosemide 40 mg)  │
│  - Target weight loss: 0.5 kg/day (no edema)      │
│    or 1 kg/day (if peripheral edema present)      │
│                                                    │
│ Grade 3 (Tense):                                   │
│  - Large-volume paracentesis (LVP)                 │
│  - Remove 5-10L                                    │
│  - Albumin 8 g per liter removed (if > 5L)         │
│  - Start/continue diuretics after LVP              │
└────────────────────────────────────────────────────┘
                         ↓
            ┌───────────────────────┐
            │ Ascites controlled?   │
            └───────────────────────┘
                 ↙              ↘
            YES                    NO
             ↓                      ↓
    Continue diuretics     REFRACTORY ASCITES
    Monitor for SBP        (5-10% of cases)
                                   ↓
                ┌──────────────────────────────────┐
                │ REFRACTORY ASCITES MANAGEMENT:   │
                │ 1. Serial large-volume LVP       │
                │    + albumin replacement          │
                │ 2. Consider TIPS (if eligible)   │
                │ 3. Liver transplant evaluation   │
                └──────────────────────────────────┘

General Measures for Ascites Management

1. Sodium Restriction:

• Target: less than 2 g sodium per day (88 mmol/day)
• Equivalent to approximately less than 5 g salt per day
• No-added-salt diet; avoid processed foods, canned goods, restaurant meals
• Effective in 10-20% of patients as monotherapy
• Fluid restriction NOT routinely required unless serum sodium less than 125 mmol/L (dilutional hyponatremia)

2. Avoid Nephrotoxic Medications:

• NSAIDs: Prostaglandin inhibition worsens renal perfusion; strongly contraindicated
• ACE inhibitors / ARBs: Risk of hypotension and renal impairment
• Aminoglycosides: Direct nephrotoxicity
• IV contrast: Risk of contrast-induced nephropathy; use cautiously with pre-hydration

3. Alcohol Abstinence:

• Mandatory for alcohol-related liver disease
• Improvement in hepatic function and potential ascites resolution

4. Treat Underlying Liver Disease:

• Antivirals for HBV/HCV
• Weight loss and metabolic control for NAFLD
• Immunosuppression for autoimmune hepatitis
• Ursodeoxycholic acid for primary biliary cholangitis/primary sclerosing cholangitis

Diuretic Therapy for Ascites

First-Line Diuretic: Spironolactone (Aldosterone Antagonist)

• Starting dose: Spironolactone 100 mg OD (single morning dose)
• Mechanism: Blocks aldosterone in distal tubule; addresses primary mechanism of sodium retention in cirrhosis
• Titration: Increase by 100 mg every 3-5 days if inadequate response (check electrolytes before each increase)
• Maximum dose: 400 mg/day

Addition of Loop Diuretic: Furosemide

• Indication: Add if inadequate response to spironolactone alone after 4-7 days
• Starting dose: Furosemide 40 mg OD
• Ratio: Maintain spironolactone:furosemide ratio of 100:40 (e.g., spironolactone 100 mg + furosemide 40 mg, or spironolactone 200 mg + furosemide 80 mg)
• Rationale for ratio: Maintains normokalemia; avoids hyperkalemia (spironolactone) or hypokalemia (furosemide)
• Maximum dose: Spironolactone 400 mg + furosemide 160 mg per day

Target Weight Loss with Diuretics:

• No peripheral edema: 0.5 kg/day (maximum rate of peritoneal reabsorption)
• With peripheral edema: 1 kg/day (additional mobilization from peripheral edema)
• Faster weight loss risks intravascular volume depletion, renal impairment, and electrolyte disturbances

Monitoring During Diuretic Therapy:

• Weigh daily (same time, same scale)
• Electrolytes (Na, K) and renal function (creatinine): Check every 3-5 days initially, then weekly once stable
• Adjust diuretics based on weight loss and laboratory parameters

Complications of Diuretic Therapy:

When to Stop Diuretics:

• Rising creatinine > 30% above baseline despite holding diuretics
• Severe hyponatremia (less than 120 mmol/L)
• Hepatic encephalopathy refractory to lactulose
• Severe hypokalemia or hyperkalemia unresponsive to dose adjustments
• Intractable muscle cramps

Large-Volume Paracentesis (LVP)

Indications:

• Tense ascites (Grade 3) causing discomfort or respiratory compromise
• Refractory ascites unresponsive to maximal diuretics
• Therapeutic relief of symptoms

Procedure:

• Remove 5-10 liters (or more) in single session
• No upper limit on volume removed if albumin administered
• Faster than diuretic therapy; complete drainage in less than 2 hours

Albumin Replacement (Post-Paracentesis Circulatory Dysfunction Prevention):

• Indication: Paracentesis > 5 liters
• Dose: 8 g of albumin per liter of ascites removed
  • "Example: 8L removed → 64g albumin (e.g., 640 mL of 10% albumin or 320 mL of 20% albumin)"
• Timing: Administer during or immediately after paracentesis
• Benefit: Reduces post-paracentesis circulatory dysfunction (PPCD), renal impairment, hyponatremia, and re-accumulation rate

Post-Paracentesis Circulatory Dysfunction (PPCD):

• Defined as increase in plasma renin activity > 50% of baseline by Day 6 post-LVP
• Clinical consequence: Renal impairment, hyponatremia, rapid re-accumulation of ascites
• Prevented by albumin infusion

After LVP:

• Resume or initiate diuretics (to prevent/delay re-accumulation)
• Monitor electrolytes and renal function

Refractory Ascites

Definition: Ascites that:

1. Cannot be mobilized, OR
2. Early recurrence after therapeutic paracentesis (LVP), despite maximal diuretic therapy (spironolactone 400 mg/day + furosemide 160 mg/day) and sodium restriction

Prevalence: 5-10% of cirrhotic patients with ascites

Management Options:

1. Serial Large-Volume Paracentesis (LVP) + Albumin

• Technique: Repeat LVP every 2-4 weeks as needed
• Albumin: 8 g per liter removed (if > 5L)
• Advantages: Safe, effective symptom relief, no shunt-related complications
• Disadvantages: Repeated procedures, cost, inconvenience, does not improve survival

2. Transjugular Intrahepatic Portosystemic Shunt (TIPS)

• Mechanism: Creates shunt between portal vein and hepatic vein, reducing portal pressure
• Efficacy: Controls ascites in 60-80%; reduces need for paracentesis
• Survival benefit: Controversial; some RCTs show improved transplant-free survival vs. LVP
• Complications:
  • "Hepatic encephalopathy: 30-50% (major limiting factor)"
  • "Shunt dysfunction/stenosis: Requires monitoring and re-intervention"
  • "Acute liver failure: Risk in patients with poor hepatic reserve"
• Contraindications:
  • Severe hepatic encephalopathy
  • Severe hepatic dysfunction (bilirubin > 5 mg/dL, Child-Pugh > 13)
  • Cardiac failure or pulmonary hypertension
  • Active infection
  • Hepatocellular carcinoma (relative)
• Patient selection: Best for younger patients with preserved liver function (Child-Pugh B, selected Child-Pugh C), refractory ascites, no prior severe encephalopathy

3. Liver Transplantation

• Definitive treatment for refractory ascites
• Refractory ascites is a MELD exception criterion in many transplant programs
• Median survival without transplant: 6 months
• Refer early to transplant center

4. Experimental/Palliative Options (Limited Evidence)

• Peritoneovenous shunt (LeVeen/Denver shunt): High complication rate (infection, thrombosis, DIC); rarely used
• Alfapump®: Implantable pump for automated peritoneal fluid transfer to bladder; limited availability
• Palliative care: For patients not transplant candidates; focus on symptom relief and quality of life

Management Algorithm for Spontaneous Bacterial Peritonitis

          SUSPECTED SBP (Cirrhosis + Unwell/Fever)
                         ↓
┌──────────────────────────────────────────────────┐
│       IMMEDIATE DIAGNOSTIC PARACENTESIS          │
│  (Before or immediately after starting empirical │
│   antibiotics; do NOT delay for coagulopathy)    │
└──────────────────────────────────────────────────┘
                         ↓
┌──────────────────────────────────────────────────┐
│         ASCITIC FLUID ANALYSIS                   │
│  - Cell count + differential (PMN)               │
│  - Gram stain + culture (inoculate blood culture │
│    bottles at bedside for maximum yield)         │
│  - Protein, albumin, glucose, LDH                │
└──────────────────────────────────────────────────┘
                         ↓
            ┌────────────────────────┐
            │ PMN ≥250/mm³?          │
            └────────────────────────┘
                 ↙              ↘
            YES                    NO
             ↓                      ↓
       DIAGNOSE SBP        PMN less than 250/mm³ + Culture Positive
             ↓                      ↓
┌──────────────────────────────────────────────────┐
│               START TREATMENT IMMEDIATELY        │
├──────────────────────────────────────────────────┤
│ 1. ANTIBIOTICS (start empirically, do NOT wait   │
│    for culture results):                         │
│    - First-line: IV Cefotaxime 2g TDS            │
│      OR IV Ceftriaxone 2g OD                     │
│    - If penicillin allergy: IV Ciprofloxacin     │
│      400mg BD OR IV Moxifloxacin 400mg OD        │
│    - If nosocomial SBP or recent quinolone       │
│      prophylaxis: Consider piperacillin-         │
│      tazobactam 4.5g TDS OR meropenem 1g TDS     │
│    - Duration: 5-7 days (can switch to PO if     │
│      clinical improvement and afebrile by Day 3) │
│                                                  │
│ 2. IV ALBUMIN (Prevents hepatorenal syndrome):  │
│    - Day 1: 1.5 g/kg (max 100g)                 │
│    - Day 3: 1 g/kg (max 100g)                   │
│    - Especially important if creatinine > 88     │
│      μmol/L (> 1 mg/dL) or bilirubin > 68 μmol/L  │
│      (> 4 mg/dL)                                 │
│                                                  │
│ 3. SUPPORTIVE CARE:                             │
│    - Stop diuretics (until infection resolved)  │
│    - Avoid nephrotoxins (NSAIDs, aminoglycosides│
│      contrast, ACE-I)                           │
│    - Monitor encephalopathy (lactulose PRN)     │
│    - Fluid resuscitation if hypotensive         │
└──────────────────────────────────────────────────┘
                         ↓
┌──────────────────────────────────────────────────┐
│           RESPONSE ASSESSMENT (48 HOURS)         │
│  - Clinical improvement (fever, pain resolved)?  │
│  - Repeat paracentesis if NO improvement:        │
│    → Expect PMN decrease by > 25%                 │
│    → If no decrease: Consider resistant organism,│
│       secondary peritonitis, or alternative Dx   │
└──────────────────────────────────────────────────┘
                         ↓
            ┌────────────────────────┐
            │ Treatment response?    │
            └────────────────────────┘
                 ↙              ↘
            YES                    NO
             ↓                      ↓
   ┌────────────────────┐    ┌──────────────────┐
   │ Complete 5-7 days  │    │ Investigate for: │
   │ antibiotics        │    │ - Resistant      │
   │                    │    │   organism       │
   │ START SECONDARY    │    │ - Secondary      │
   │ PROPHYLAXIS:       │    │   peritonitis    │
   │ - Norfloxacin      │    │ - Alternative Dx │
   │   400mg OD PO      │    │                  │
   │   OR               │    │ Consider:        │
   │ - Ciprofloxacin    │    │ - Broaden Abx    │
   │   500mg OD PO      │    │ - CT abdomen     │
   │   LIFELONG         │    │ - Surgical review│
   └────────────────────┘    └──────────────────┘

Acute Treatment of SBP

Antibiotics:

First-Line (Community-Acquired SBP):

• IV Cefotaxime 2g TDS (every 8 hours) for 5-7 days
  • OR IV Ceftriaxone 2g OD (once daily) for 5-7 days
  • Third-generation cephalosporins cover common Gram-negative organisms (E. coli, Klebsiella) and most Gram-positives
  • Can switch to oral if afebrile and clinically improved by Day 3

Alternative (if Penicillin Allergy):

• IV Ciprofloxacin 400mg BD (if no prior quinolone prophylaxis)
• IV Moxifloxacin 400mg OD

Nosocomial SBP or Recent Quinolone Prophylaxis:

• Higher risk of multidrug-resistant (MDR) organisms (ESBL, MRSA, VRE, Pseudomonas)
• Broad-spectrum therapy:
  • Piperacillin-tazobactam 4.5g TDS (every 8 hours)
  • Meropenem 1g TDS (if severe sepsis or high ESBL prevalence)
• De-escalate based on culture results

Duration:

• 5-7 days total
• Oral switch (e.g., ciprofloxacin 500mg BD, amoxicillin-clavulanate) acceptable if afebrile and clinically improved by Day 3

Intravenous Albumin (Essential Component of SBP Treatment):

Landmark Evidence: Sort et al., NEJM 1999 (PMID: 10432325)

• RCT of 126 SBP patients: cefotaxime alone vs. cefotaxime + IV albumin
• Results:
  • "Hepatorenal syndrome: 33% (antibiotics alone) vs. 10% (antibiotics + albumin)"
  • "In-hospital mortality: 29% vs. 10%"
  • NNT = 5 to prevent one death

Albumin Dosing Protocol:

• Day 1: 1.5 g/kg IV (up to maximum 100 g)
  • "Example: 70 kg patient → 105g → give 100g (maximum)"
  • Administer as 20% albumin solution (500 mL contains 100g)
• Day 3: 1 g/kg IV (up to maximum 100 g)
  • "Example: 70 kg patient → 70g albumin"

Indications for Albumin:

• All SBP patients (especially high-risk):
  • Creatinine > 88 μmol/L (> 1 mg/dL)
  • Bilirubin > 68 μmol/L (> 4 mg/dL)
  • Blood urea nitrogen (BUN) > 30 mg/dL
• Lower-risk patients (creatinine less than 88 μmol/L, bilirubin less than 68 μmol/L) may have less absolute benefit, but albumin still recommended as standard of care

Mechanism of Albumin Benefit:

• Volume expansion reduces renal hypoperfusion
• Albumin binds endotoxin and reduces systemic inflammation
• Improves cardiac output and circulatory function

Supportive Care:

Response Assessment

Clinical Improvement Expected by 48 Hours:

• Defervescence (afebrile)
• Reduced abdominal pain
• Improved mental status
• Hemodynamic stability

Repeat Paracentesis at 48 Hours (if no clinical improvement):

• Expect PMN decrease by > 25% from baseline
• If PMN not declining:
  • "Resistant organism: Review cultures, broaden antibiotics"
  • "Secondary bacterial peritonitis: Obtain CT abdomen; surgical consultation"
  • "Alternative diagnosis: Reconsider SBP diagnosis"

Treatment Failure:

• No clinical improvement by 48-72 hours
• Rising or static PMN count on repeat paracentesis
• Positive blood or ascitic cultures with resistant organism

Management of Treatment Failure:

• Broaden antibiotic coverage (e.g., meropenem, vancomycin if MRSA suspected)
• CT abdomen to exclude secondary peritonitis (perforation, abscess, ischemic bowel)
• Surgical consultation if imaging suggests surgical abdomen
• Review microbiology and adjust antibiotics based on sensitivities

Prophylaxis for SBP

Primary Prophylaxis (Before First Episode):

Indications:

1. Ascitic protein less than 15 g/L (less than 1.5 g/dL) PLUS any of:
   • Renal impairment (creatinine > 106 μmol/L or > 1.2 mg/dL, OR BUN > 25 mg/dL)
   • Severe liver disease (Child-Pugh ≥9 with bilirubin ≥3 mg/dL)
   • Serum sodium less than 130 mmol/L
2. Active GI bleeding (variceal hemorrhage):
   • High risk of bacterial translocation and SBP (20-40%)
   • Prophylaxis reduces infection and mortality

Regimens:

• Norfloxacin 400 mg OD PO (daily, long-term for indication #1; 7 days for GI bleeding)
• Ciprofloxacin 500 mg OD PO (alternative to norfloxacin)
• Ceftriaxone 1g IV OD for 7 days (if active GI bleeding and inpatient; superior to oral quinolones in this setting)

Evidence:

• Fernandez et al., Gastroenterology 2007 (PMID: 17854593): Norfloxacin in patients with low ascitic protein reduced SBP, hepatorenal syndrome, and improved survival

Secondary Prophylaxis (After First Episode of SBP):

Indication:

• All patients who have had one episode of SBP

Regimen:

• Norfloxacin 400 mg OD PO OR Ciprofloxacin 500 mg OD PO
• Duration: Lifelong (or until ascites resolves completely or patient transplanted)

Evidence:

• Reduces 1-year SBP recurrence from 70% to less than 20%
• Improves survival

Alternative (if quinolone resistance or intolerance):

• Co-trimoxazole (trimethoprim-sulfamethoxazole) 960 mg OD (single-strength daily or double-strength 3 times per week)

Concern: Quinolone Resistance:

• Long-term quinolone prophylaxis selects for resistant organisms
• Nosocomial SBP in patients on quinolones often caused by quinolone-resistant Gram-negatives or Gram-positives (Enterococcus, MRSA)
• If SBP develops on quinolone prophylaxis, use broad-spectrum empirical antibiotics (piperacillin-tazobactam or carbapenem)

Disposition and Follow-Up

Admission:

• All patients with SBP require hospitalization
• Ward vs. ICU/HDU based on severity:
  • "ICU/HDU indications: Septic shock, multi-organ failure, severe hepatic encephalopathy (Grade III-IV), respiratory failure, hepatorenal syndrome"

Follow-Up After Discharge:

• Hepatology clinic within 2-4 weeks
• Liver transplant evaluation (SBP is marker of decompensated cirrhosis; median survival 6-12 months without transplant)
• Ensure adherence to lifelong secondary prophylaxis
• Monitor for ascites recurrence (diuretics, sodium restriction)
• Screen for hepatocellular carcinoma (6-month ultrasound + AFP if cirrhotic)

---

8. Complications

Complications of Ascites

Immediate Complications

Early Complications (Days to Weeks)

Late Complications (Months to Years)

Complications of Spontaneous Bacterial Peritonitis

Immediate Complications

Early Complications (Days-Weeks)

• Treatment failure (5-10%): Resistant organism, secondary peritonitis, inadequate antibiotic coverage
• Recurrent SBP (70% at 1 year without prophylaxis): Prevented by lifelong secondary prophylaxis
• Progressive liver failure: SBP accelerates hepatic decompensation

Late Complications (Months)

• Mortality: In-hospital 20-40%; 30-day 25-30%; 1-year 50-70%
• Recurrence: 70% at 1 year without prophylaxis; less than 20% with prophylaxis
• Need for liver transplant: SBP is a marker of advanced disease; median survival 6-12 months; transplant evaluation essential

---

9. Prognosis & Outcomes

Ascites Prognosis

Prognostic Factors in Ascites

Good Prognosis:

• Low MELD score (less than 15)
• Child-Pugh A or low B score
• Ascites controlled with diuretics
• No complications (SBP, hepatorenal syndrome, encephalopathy)
• Alcohol abstinence (if alcohol-related cirrhosis)
• Successful treatment of underlying liver disease (viral suppression, metabolic control)

Poor Prognosis:

• High MELD score (> 20)
• Child-Pugh C
• Refractory ascites
• Hepatorenal syndrome
• Recurrent SBP
• Hyponatremia (less than 130 mmol/L)
• Malnutrition and sarcopenia
• Hepatocellular carcinoma
• Ongoing alcohol or substance use

SBP Prognosis

Prognostic Factors in SBP

Good Prognosis:

• Low baseline MELD score (less than 15)
• Prompt diagnosis and treatment (less than 24 hours from symptom onset)
• Community-acquired SBP (vs. nosocomial)
• Sensitive organism (susceptible to first-line antibiotics)
• No hepatorenal syndrome
• No septic shock
• Bilirubin less than 68 μmol/L (less than 4 mg/dL)
• Creatinine less than 88 μmol/L (less than 1 mg/dL)
• PMN count decrease > 25% at 48 hours

Poor Prognosis:

• High MELD score (> 20)
• Delayed diagnosis (> 24-48 hours)
• Nosocomial SBP (higher rates of MDR organisms, treatment failure)
• Multidrug-resistant organism
• Hepatorenal syndrome (30% incidence; in-hospital mortality > 50%)
• Septic shock (mortality > 60%)
• High bilirubin (> 68 μmol/L or > 4 mg/dL)
• Renal impairment (creatinine > 88 μmol/L or > 1 mg/dL)
• Hepatic encephalopathy (Grade III-IV)
• Upper GI bleeding (concurrent or recent)
• Acute-on-chronic liver failure

Predictive Scores:

• MELD score: Most widely used; incorporates creatinine, bilirubin, INR; predicts 3-month mortality
• Child-Pugh score: Ascites, encephalopathy, bilirubin, albumin, INR; stratifies into A/B/C (increasing severity)

Impact of Treatment on Prognosis

Albumin + Antibiotics (Sort et al., NEJM 1999):

• Reduced in-hospital mortality from 29% to 10%
• Reduced hepatorenal syndrome from 33% to 10%
• NNT = 5 to prevent one death

Secondary Prophylaxis:

• Reduces 1-year SBP recurrence from 70% to less than 20%
• Improves 1-year survival

TIPS for Refractory Ascites:

• Controls ascites in 60-80%
• May improve transplant-free survival in selected patients
• Risk of hepatic encephalopathy (30-50%)

Liver Transplantation:

• Definitive treatment for decompensated cirrhosis with ascites
• 1-year survival post-transplant: 85-90%
• 5-year survival post-transplant: 70-80%

---

10. Evidence & Guidelines

Key Guidelines

1. European Association for the Study of the Liver (EASL) Clinical Practice Guidelines for the Management of Patients with Decompensated Cirrhosis. J Hepatol. 2018;69(2):406-460. [PMID: 29653741]

   • Comprehensive guideline covering ascites, SBP, hepatorenal syndrome, and other complications of cirrhosis

2. Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(2):1014-1048. [PMID: 33942342]

   • Updated AASLD guidance on ascites and SBP management

3. Runyon BA, AASLD Practice Guidelines Committee. Management of Adult Patients with Ascites Due to Cirrhosis: Update 2012. Hepatology. 2013;57(4):1651-1653. [PMID: 23463403]

   • Practical AASLD update focused on paracentesis, diuretics, and SBP diagnosis

4. Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal Hypertensive Bleeding in Cirrhosis: Risk Stratification, Diagnosis, and Management: 2016 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2017;65(1):310-335. [PMID: 27786365]

   • Covers portal hypertension and bleeding, including SBP prophylaxis in GI bleeding

5. Piano S, Tonon M, Angeli P. Management of Ascites and Hepatorenal Syndrome. Hepatol Int. 2018;12(Suppl 1):122-134. [PMID: 29427092]

   • Focused review on ascites and hepatorenal syndrome pathophysiology and treatment

Key Trials and Landmark Studies

SBP and Albumin:

1. Sort P, Navasa M, Arroyo V, et al. Effect of Intravenous Albumin on Renal Impairment and Mortality in Patients with Cirrhosis and Spontaneous Bacterial Peritonitis. N Engl J Med. 1999;341(6):403-409. [PMID: 10432325]
   • Design: RCT of 126 SBP patients; cefotaxime alone vs. cefotaxime + IV albumin (1.5 g/kg Day 1, 1 g/kg Day 3)
   • Key Finding: Albumin reduced hepatorenal syndrome (10% vs. 33%) and in-hospital mortality (10% vs. 29%)
   • Impact: Established IV albumin as standard of care in SBP treatment

SBP Prophylaxis:

2. Fernández J, Navasa M, Planas R, et al. Primary Prophylaxis of Spontaneous Bacterial Peritonitis Delays Hepatorenal Syndrome and Improves Survival in Cirrhosis. Gastroenterology. 2007;133(3):818-824. [PMID: 17854593]

   • Design: RCT of 68 cirrhotic patients with low ascitic protein (less than 15 g/L) randomized to norfloxacin vs. placebo
   • Key Finding: Norfloxacin reduced SBP (7% vs. 61%), hepatorenal syndrome (28% vs. 41%), and improved 1-year survival (94% vs. 62%)
   • Impact: Established primary prophylaxis indication for high-risk patients (low ascitic protein)

3. Terg R, Fassio E, Guevara M, et al. Ciprofloxacin in Primary Prophylaxis of Spontaneous Bacterial Peritonitis: A Randomized, Placebo-Controlled Study. J Hepatol. 2008;48(5):774-779. [PMID: 18308416]

   • Confirmed efficacy of ciprofloxacin for primary SBP prophylaxis

4. Runyon BA. Low-Protein-Concentration Ascitic Fluid is Predisposed to Spontaneous Bacterial Peritonitis. Gastroenterology. 1986;91(6):1343-1346. [PMID: 3770364]

   • Landmark study identifying ascitic protein less than 15 g/L as major risk factor for SBP

Diuretics and Ascites Management:

5. Angeli P, Fasolato S, Mazza E, et al. Combined versus Sequential Diuretic Treatment of Ascites in Non-Azotaemic Patients with Cirrhosis: Results of an Open Randomised Clinical Trial. Gut. 2010;59(1):98-104. [PMID: 19570762]
   • Design: RCT comparing spironolactone alone vs. spironolactone + furosemide (100:40 ratio) as initial therapy
   • Key Finding: Combination therapy achieved faster ascites control with similar safety
   • Impact: Supports combination diuretic approach (spironolactone + furosemide in 100:40 ratio) from initiation

Large-Volume Paracentesis and Albumin:

6. Ginès P, Titó L, Arroyo V, et al. Randomized Comparative Study of Therapeutic Paracentesis with and without Intravenous Albumin in Cirrhosis. Gastroenterology. 1988;94(6):1493-1502. [PMID: 3360270]
   • Design: RCT of 105 patients; LVP with albumin (8 g/L removed) vs. LVP without albumin
   • Key Finding: Albumin reduced post-paracentesis circulatory dysfunction, hyponatremia, and renal impairment
   • Impact: Established albumin replacement for LVP > 5L

TIPS for Refractory Ascites:

7. Bureau C, Thabut D, Oberti F, et al. Transjugular Intrahepatic Portosystemic Shunts with Covered Stents Increase Transplant-Free Survival of Patients with Cirrhosis and Recurrent Ascites. Gastroenterology. 2017;152(1):157-163. [PMID: 27639806]

   • Design: RCT of 62 patients; TIPS with covered stents vs. LVP for refractory ascites
   • Key Finding: TIPS improved transplant-free survival (93% vs. 52% at 1 year) but increased encephalopathy
   • Impact: TIPS is effective for refractory ascites in carefully selected patients

8. Salerno F, Merli M, Riggio O, et al. Randomized Controlled Study of TIPS versus Paracentesis Plus Albumin in Cirrhosis with Severe Ascites. Hepatology. 2004;40(3):629-635. [PMID: 15349902]

   • Meta-analysis: TIPS controls ascites better than LVP but does not clearly improve survival; encephalopathy is a major limitation

Hepatorenal Syndrome:

9. Martín-Llahí M, Pépin MN, Guevara M, et al.; TAHRS Investigators. Terlipressin and Albumin vs Albumin in Patients with Cirrhosis and Hepatorenal Syndrome: A Randomized Study. Gastroenterology. 2008;134(5):1352-1359. [PMID: 18471512]
   • Design: RCT of 46 HRS patients; terlipressin + albumin vs. albumin alone
   • Key Finding: Terlipressin + albumin reversed HRS in 77% vs. 25% (albumin alone)
   • Impact: Terlipressin + albumin is first-line therapy for hepatorenal syndrome Type 1

Bacterial Translocation and Pathophysiology:

10. Wiest R, Lawson M, Geuking M. Pathological Bacterial Translocation in Liver Cirrhosis. J Hepatol. 2014;60(1):197-209. [PMID: 23993913]

    • Comprehensive review of bacterial translocation mechanisms in cirrhosis

11. Runyon BA, Canawati HN, Akriviadis EA. Optimization of Ascitic Fluid Culture Technique. Gastroenterology. 1988;95(5):1351-1355. [PMID: 3049216]

    • Demonstrated that bedside inoculation of ascitic fluid into blood culture bottles increases culture yield from 40% to 80%

Evidence Strength Summary

---

11. Patient/Layperson Explanation

What is Ascites?

Ascites is a build-up of fluid in your tummy (abdomen). It happens when your liver is damaged and can't work properly. This is most commonly caused by cirrhosis (scarring of the liver), which can result from long-term alcohol use, viral hepatitis, or other liver diseases. When the liver is scarred, blood flow through it becomes difficult, causing pressure to build up in the blood vessels. This pressure, combined with low protein levels in the blood, forces fluid to leak out into the space around your organs.

What is Spontaneous Bacterial Peritonitis (SBP)?

SBP is an infection of the fluid in your tummy (ascites). It happens when bacteria from your gut get into this fluid. It is a serious complication that requires urgent treatment with antibiotics and albumin (a protein given through a drip).

Why Does It Matter?

Ascites:

• Ascites means your liver disease has become more serious
• Without treatment, it can cause discomfort, difficulty breathing, and other complications
• It affects your prognosis: people with ascites have a shorter life expectancy than those without
• Early treatment and lifestyle changes can help control the fluid and improve your quality of life

SBP:

• Without treatment, SBP can quickly become life-threatening
• It can damage your kidneys (hepatorenal syndrome) and cause organ failure
• If treated promptly with antibiotics and albumin (a protein given through a drip), most people recover
• After one episode, you need to take antibiotics every day for life to prevent it coming back

How is Ascites Treated?

1. Reduce salt in your diet: Eat less than 2 grams of sodium per day (about one teaspoon of salt total)

   • Avoid processed foods, canned foods, restaurant meals
   • Read food labels carefully

2. Water tablets (diuretics): Help your kidneys remove the extra fluid

   • Usually spironolactone (and sometimes furosemide as well)
   • You will need to weigh yourself daily and have regular blood tests

3. Drainage (paracentesis): If you have a lot of fluid causing discomfort or breathing problems, your doctor can drain it with a needle

   • This is a quick procedure done at the bedside or clinic
   • You will receive albumin through a drip to prevent complications

4. Treat the underlying liver disease: If possible (e.g., stop drinking alcohol, treat hepatitis)

5. Advanced treatments: If fluid keeps coming back despite tablets (called "refractory ascites"), you may need:

   • Regular drainage procedures
   • A TIPS procedure (a shunt placed inside your liver to reduce pressure)
   • Liver transplant evaluation

How is SBP Treated?

1. Antibiotics: Given through a drip immediately when SBP is suspected

   • Usually cefotaxime or ceftriaxone
   • Treatment lasts 5-7 days

2. Albumin infusion: A protein given through a drip on Day 1 and Day 3 to protect your kidneys and reduce the risk of complications

3. Preventing recurrence: After you recover, you will need to take an antibiotic tablet (norfloxacin or ciprofloxacin) every day for life to stop the infection coming back

What to Expect

With Ascites:

• You will need regular clinic appointments and blood tests
• You may need drainage procedures if fluid builds up
• Your doctor may discuss liver transplant if your liver disease is advanced
• Stick to a low-salt diet and take your tablets every day

With SBP:

• You will need to stay in hospital for at least 5-7 days for intravenous antibiotics
• Most people start to feel better within 2-3 days
• After recovery, you will need to take a daily antibiotic tablet to prevent the infection from coming back
• Your doctor may discuss liver transplant, as SBP is a sign of advanced liver disease

When to Seek Urgent Medical Help

Go to A&E or call 999 if you have liver disease and ascites, and you develop:

• Fever or chills (even low-grade fever)
• Tummy pain or tenderness
• Confusion, drowsiness, or unusual sleepiness
• Vomiting blood or passing black stools (signs of internal bleeding)
• Difficulty breathing or shortness of breath
• Reduced urine output (not passing water)
• Feeling very unwell, faint, or dizzy

These symptoms could indicate SBP, hepatorenal syndrome, or other serious complications requiring immediate treatment.

Lifestyle and Self-Care

• Avoid alcohol completely if your liver disease is alcohol-related
• Low-salt diet: Less than 2 grams of sodium per day
• Weigh yourself daily: Report sudden weight gain (> 1 kg in a few days) to your doctor
• Take your medications as prescribed: Diuretics, prophylactic antibiotics, and other liver medications
• Avoid NSAIDs (e.g., ibuprofen, naproxen): These can harm your kidneys
• Regular follow-up: Attend all clinic appointments and have regular blood tests and imaging

---

12. References

Primary Guidelines

1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the Management of Patients with Decompensated Cirrhosis. J Hepatol. 2018;69(2):406-460. PMID: 29653741

2. Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(2):1014-1048. PMID: 33942342

3. Runyon BA; AASLD Practice Guidelines Committee. Management of Adult Patients with Ascites Due to Cirrhosis: Update 2012. Hepatology. 2013;57(4):1651-1653. PMID: 23463403

4. Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal Hypertensive Bleeding in Cirrhosis: Risk Stratification, Diagnosis, and Management: 2016 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2017;65(1):310-335. PMID: 27786365

Key Trials – SBP and Albumin

5. Sort P, Navasa M, Arroyo V, et al. Effect of Intravenous Albumin on Renal Impairment and Mortality in Patients with Cirrhosis and Spontaneous Bacterial Peritonitis. N Engl J Med. 1999;341(6):403-409. PMID: 10432325

6. Fernández J, Navasa M, Planas R, et al. Primary Prophylaxis of Spontaneous Bacterial Peritonitis Delays Hepatorenal Syndrome and Improves Survival in Cirrhosis. Gastroenterology. 2007;133(3):818-824. PMID: 17854593

7. Runyon BA, Canawati HN, Akriviadis EA. Optimization of Ascitic Fluid Culture Technique. Gastroenterology. 1988;95(5):1351-1355. PMID: 3049216

8. Runyon BA. Low-Protein-Concentration Ascitic Fluid is Predisposed to Spontaneous Bacterial Peritonitis. Gastroenterology. 1986;91(6):1343-1346. PMID: 3770364

Ascites Management and Diuretics

9. Ginès P, Titó L, Arroyo V, et al. Randomized Comparative Study of Therapeutic Paracentesis with and without Intravenous Albumin in Cirrhosis. Gastroenterology. 1988;94(6):1493-1502. PMID: 3360270

10. Angeli P, Fasolato S, Mazza E, et al. Combined versus Sequential Diuretic Treatment of Ascites in Non-Azotaemic Patients with Cirrhosis: Results of an Open Randomised Clinical Trial. Gut. 2010;59(1):98-104. PMID: 19570762

11. Runyon BA. Management of Adult Patients with Ascites Due to Cirrhosis. Hepatology. 2004;39(3):841-856. PMID: 14999706

SAAG and Diagnostic Approach

12. Runyon BA, Montano AA, Akriviadis EA, et al. The Serum-Ascites Albumin Gradient is Superior to the Exudate-Transudate Concept in the Differential Diagnosis of Ascites. Ann Intern Med. 1992;117(3):215-220. PMID: 1616215

TIPS for Refractory Ascites

13. Bureau C, Thabut D, Oberti F, et al. Transjugular Intrahepatic Portosystemic Shunts with Covered Stents Increase Transplant-Free Survival of Patients with Cirrhosis and Recurrent Ascites. Gastroenterology. 2017;152(1):157-163. PMID: 27639806

14. Salerno F, Merli M, Riggio O, et al. Randomized Controlled Study of TIPS versus Paracentesis Plus Albumin in Cirrhosis with Severe Ascites. Hepatology. 2004;40(3):629-635. PMID: 15349902

Hepatorenal Syndrome

15. Martín-Llahí M, Pépin MN, Guevara M, et al.; TAHRS Investigators. Terlipressin and Albumin vs Albumin in Patients with Cirrhosis and Hepatorenal Syndrome: A Randomized Study. Gastroenterology. 2008;134(5):1352-1359. PMID: 18471512

16. Angeli P, Ginès P, Wong F, et al. Diagnosis and Management of Acute Kidney Injury in Patients with Cirrhosis: Revised Consensus Recommendations of the International Club of Ascites. Gut. 2015;64(4):531-537. PMID: 25631669

Pathophysiology and Bacterial Translocation

17. Wiest R, Lawson M, Geuking M. Pathological Bacterial Translocation in Liver Cirrhosis. J Hepatol. 2014;60(1):197-209. PMID: 23993913

18. Schrier RW, Arroyo V, Bernardi M, et al. Peripheral Arterial Vasodilation Hypothesis: A Proposal for the Initiation of Renal Sodium and Water Retention in Cirrhosis. Hepatology. 1988;8(5):1151-1157. PMID: 2971015

Multidrug-Resistant Organisms and Nosocomial SBP

19. Piano S, Fasolato S, Salinas F, et al. The Empirical Antibiotic Treatment of Nosocomial Spontaneous Bacterial Peritonitis: Results of a Randomized, Controlled Trial. Hepatology. 2016;63(4):1299-1309. PMID: 26660389

Albumin Mechanisms and Outcomes

20. Bai Z, Xu X, Shrestha A, et al. Use of Albumin Infusion in Cirrhotic Patients: An International Position Statement. JHEP Rep. 2023;5(7):100776. PMID: 37456673

21. Garcia-Martinez R, Caraceni P, Bernardi M, et al. Albumin: Pathophysiologic Basis of Its Role in the Treatment of Cirrhosis and Its Complications. Hepatology. 2013;58(5):1836-1846. PMID: 23423799

Comprehensive Reviews

22. Moore KP, Aithal GP. Guidelines on the Management of Ascites in Cirrhosis. Gut. 2006;55(Suppl 6):vi1-vi12. PMID: 16966752

---

Last Reviewed: 2026-01-09 | MedVellum Editorial Team

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and refer to the most current guidelines and evidence.